apt: adjuvant paclitaxel and trastuzumab for node-negative, her2 breast cancer
Published 1 year ago • 3.8K plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
6:17
sara tolaney, sabcs 2022: adjuvant paclitaxel and trastuzumab for node-negative her2 breast cancer
-
2:52
5-year correlative analysis of atempt: adjuvant t-dm1 vs paclitaxel trastuzumab for stage i her2 bc
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
4:16
adjuvant treatment for stage i her2 breast cancer
-
1:59
adapt: de-escalated neoadjuvant pertuzumab trastuzumab with or without paclitaxel in hr-/her2 ebc
-
4:26
dr. sara tolaney on adjuvant t-dm1 vs paclitaxel and trastuzumab for stage i her2 breast cancer
-
3:11
st. gallen consensus 2021: neoadjuvant and adjuvant therapy for her2 breast cancer
-
0:59
dr. burstein on the results of the apt trial for her2 breast cancer
-
1:56
persephone: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
-
1:06
meteora-ii: metronomic vex versus paclitaxel in er /her2- metastatic breast cancer
-
3:46
aphinity: 6-year follow-up results of dual her2 blockade in her2 breast cancer
-
8:16
apt for her2 breast cancer patients with small tumours
-
3:16
her-ram: investigating trastuzumab, ramucirumab and paclitaxel for the second-line treatment of gc
-
4:29
pertuzumab, trastuzumab and cyclophosphamide in older patients with her2 breast cancer
-
1:47
can we decrease chemotherapy in ln premenopausal women based on genomic tests?
-
52:21
new & supporting data for optimizing therapy in her2 breast cancer | dr. irene and dr. vogel
-
1:12
trastuzumab deruxtecan in metastatic her2 breast cancer
-
5:19
tailorx: an update incl 12-year event rates in woman with er lymph node-negative breast cancer
-
1:11
an unanswerable question? adjuvant and neoadjuvant treatment of breast cancer